Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update

This publication has 10 references indexed in Scilit:

• Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis.
  2000
• Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats.
  1999
• PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases
  Annals of the Rheumatic Diseases, 1999
• Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats
  American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1999
• Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats
  Inflammation Research, 1999
• Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy.
  1999
• Spinal epidural hematoma complicating active systemic lupus erythematosus
  Arthritis & Rheumatism, 1999
• DIFFERENT ROLES OF TUMOUR NECROSIS FACTOR α AND INTERLEUKIN 1 IN MURINE STREPTOCOCCAL CELL WALL ARTHRITIS
  Cytokine, 1998
• Pharmacokinetics, immunogenicity, and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboon
  Journal of Applied Physiology, 1998
• Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor
  Arthritis & Rheumatism, 1998